Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$1,147,670.00
Jan 1, 2014
Retinitis Pigmentosa diagnosis and therapy: retinal remodeling and optogenetic reactivation of degenerated retina
$388,752.00
Jan 1, 2014
Targeted delivery of antisense-mediated exon skipping therapy in transgenic pig model of DMD
$388,800.00
Jan 1, 2014
Systematic identification of dynamic epigenetic modifications in DNA damage repair for novel cancer therapy
$52,500.00
Jan 1, 2014
Functional characterization of the Gct1 gene product in a mouse ovarian tumour model: genetics, biology and translation
$100,000.00
Dec 1, 2013
Effects of Gene-Gene Interactions within an Early Risk Pathway for Alzheimer's Disease on Established and Novel MRI-based Phenotypes
$99,957.00
Nov 1, 2013
Comparative safety and effectiveness of antiretroviral therapies
$28,980.00
Oct 2, 2013
$140,000.00
Oct 1, 2013
Dosage CIN: A comprehensive analysis of gene dosage effects on genome stability
$148,348.00
Oct 1, 2013
Prognostic gene signature for stage I lung adenocarcinoma
$192,620.00
Oct 1, 2013
Reassessment of Anti-Platelet therapy using InDividualized Strategies - Modifying Acute CoroNary Syndrome Algorithms based on Genetic and Demographic Evaluation: The RAPID-MANAGE Pilot study